Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2

Molecular Pain

Volumn 7, Issue , 2011, Pages

  Lam, Hoa ^a   Maga, Matthew ^a   Pradhan, Amynah ^a   Evans, Christopher J ^a   Maidment, Nigel T ^a   Hales, Tim G ^b   Walwyn, Wendy ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6ALPHA NALOXONE; 6BETA NALOXONE; BETA ARRESTIN 2; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTREXOL; NALTREXONE; UNCLASSIFIED DRUG; BETA ARRESTIN; CTAP OCTAPEPTIDE; PEPTIDE FRAGMENT; RETINA S ANTIGEN; SOMATOSTATIN;

ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NERVE CELL; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; WITHDRAWAL REFLEX; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ELECTROPHYSIOLOGY; GENETICS; METABOLISM; MOUSE MUTANT; PAIN ASSESSMENT; SPINAL GANGLION;

ANIMALS; ARRESTINS; ELECTROPHYSIOLOGY; FEMALE; GANGLIA, SPINAL; MALE; MICE; MICE, MUTANT STRAINS; NALOXONE; NALTREXONE; PAIN MEASUREMENT; PEPTIDE FRAGMENTS; RECEPTORS, OPIOID, MU; SOMATOSTATIN;

EID: 79953863397     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-7-24     Document Type: Article

References (40)

1. Costa T, Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 1989, 86:7321-5. 10.1073/pnas.86.19.7321, 298053, 2552439.
2. Burford NT, Wang D, Sadee W. G-protein coupling of mu-opioid receptors (OP3): elevated basal signalling activity. Biochem J 2000, 348(Pt 3):531-7. 10.1042/0264-6021:3480531, 1221094, 10839983.
3. Brillet K, Kieffer BL, Massotte D. Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening. BMC Pharmacol 2003, 3:14. 10.1186/1471-2210-3-14, 317294, 14641935.
4. Sadee W, Wang Z. Agonist induced constitutive receptor activation as a novel regulatory mechanism. Mu receptor regulation. Adv Exp Med Biol 1995, 373:85-90.
5. Bilsky EJ, Giuvelis D, Osborn MD, Dersch CM, Xu H, Rothman RB. In vitro and in vivo assessment of mu opioid receptor constitutive activity. Methods Enzymol 2010, 484:413-43. full_text, 21036244.
6. Connor M, Traynor J. Constitutively active μ-opioid receptors. Methods Enzymol 2010, 484:445-69. full_text, 21036245.
7. Liu JG, Prather PL. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment. Mol Pharmacol 2001, 60:53-62.
8. Liu JG, Ruckle MB, Prather PL. Constitutively active mu-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2,N-MePhe4,Gly-ol5]enkephalin. J Biol Chem 2001, 276:37779-86.
9. Wang D, Raehal KM, Bilsky EJ, Sadee W. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J Neurochem 2001, 77:1590-600. 10.1046/j.1471-4159.2001.00362.x, 11413242.
10. Raehal KM, Lowery JJ, Bhamidipati CM, Paolino RM, Blair JR, Wang D, Sadee W, Bilsky EJ. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther 2005, 313:1150-62. 10.1124/jpet.104.082966, 15716384.
11. Wang D, Raehal KM, Lin ET, Lowery JJ, Kieffer BL, Bilsky EJ, Sadee W. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 2004, 308:512-20. 10.1124/jpet.103.054049, 14600246.
12. Shoblock JR, Maidment NT. Constitutively active micro opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice. Neuropsychopharmacology 2006, 31:171-7.
13. Shoblock JR, Maidment NT. Enkephalin release promotes homeostatic increases in constitutively active mu opioid receptors during morphine withdrawal. Neuroscience 2007, 149:642-9. 10.1016/j.neuroscience.2007.05.011, 17905519.
14. Williams JT, Christie MJ, Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 2001, 81:299-343.
15. Ikeda SR. Voltage-dependent modulation of N-type calcium channels by G-protein beta gamma subunits. Nature 1996, 380:255-8. 10.1038/380255a0, 8637575.
16. Beedle AM, McRory JE, Poirot O, Doering CJ, Altier C, Barrere C, Hamid J, Nargeot J, Bourinet E, Zamponi GW. Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat Neurosci 2004, 7:118-25. 10.1038/nn1180, 14730309.
17. Walwyn W, Evans CJ, Hales TG. Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci 2007, 27:5092-104. 10.1523/JNEUROSCI.1157-07.2007, 17494695.
18. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999, 286:2495-8. 10.1126/science.286.5449.2495, 10617462.
19. Yoburn BC, Cohen A, Umans JG, Ling GS, Inturrisi CE. The graded and quantal nature of opioid analgesia in the rat tailflick assay. Brain Res 1985, 331:327-36. 10.1016/0006-8993(85)91558-6, 3986573.
20. Hargreaves K, Dubner R, Brown F, Flores C, Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88. 10.1016/0304-3959(88)90026-7, 3340425.
21. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994, 53:55-63. 10.1016/0165-0270(94)90144-9, 7990513.
22. Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Massotte D, Gaveriaux-Ruff C, Kieffer BL. In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS One 2009, 4:e5425. 10.1371/journal.pone.0005425, 2672171, 19412545.
23. Skoubis PD, Matthes HW, Walwyn WM, Kieffer BL, Maidment NT. Naloxone fails to produce conditioned place aversion in [mu]-opioid receptor knock-out mice. Neuroscience 2001, 106:757. 10.1016/S0306-4522(01)00333-5, 11682161.
24. Bourinet E, Soong TW, Stea A, Snutch TP. Determinants of the G protein-dependent opioid modulation of neuronal calcium channels. Proc Natl Acad Sci USA 1996, 93:1486-91. 10.1073/pnas.93.4.1486, 39966, 8643659.
25. Abbruscato TJ, Thomas SA, Hruby VJ, Davis TP. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine. J Pharmacol Exp Ther 1997, 280:402-9.
26. Bohn LM, Lefkowitz RJ, Caron MG. Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci 2002, 22:10494-500.
27. Divin MF, Holden Ko MC, Traynor JR. Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naive and morphine-dependent mice. Eur J Pharmacol 2008, 583:48-55. 10.1016/j.ejphar.2008.01.004, 3010382, 18275956.
28. Divin MF, Bradbury FA, Carroll FI, Traynor JR. Neutral antagonist activity of naltrexone and 6beta-naltrexol in naive and opioid-dependent C6 cells expressing a mu-opioid receptor. Br J Pharmacol 2009, 156:1044-53. 10.1111/j.1476-5381.2008.00035.x, 2697693, 19220294.
29. Wang D, Sun X, Sadee W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther 2007, 321:544-52. 10.1124/jpet.106.118810, 17267582.
30. Walker EA, Sterious SN. Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence. Br J Pharmacol 2005, 145:975-83. 10.1038/sj.bjp.0706247, 1576205, 15912139.
31. Connor M. Shadows across mu-Star? Constitutively active mu-opioid receptors revisited. Br J Pharmacol 2009, 156:1041-3. 10.1111/j.1476-5381.2009.00067.x, 2697690, 19368530.
32. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques BP, Kieffer BL. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996, 383:819-23. 10.1038/383819a0, 8893006.
33. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, Kieffer BL, Basbaum AI. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009, 137:1148-59. 10.1016/j.cell.2009.04.019, 19524516.
34. Haberstock-Debic H, Kim KA, Yu YJ, von Zastrow M. Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J Neurosci 2005, 25:7847-57. 10.1523/JNEUROSCI.5045-04.2005, 16120787.
35. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000, 408:720-3. 10.1038/35047086, 11130073.
36. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008, 154:384-96. 10.1038/bjp.2008.100, 2442443, 18414400.
37. Luan B, Zhao J, Wu H, Duan B, Shu G, Wang X, Li D, Jia W, Kang J, Pei G. Deficiency of a beta-arrestin-2 signal complex contributes to insulin resistance. Nature 2009, 457:1146-9. 10.1038/nature07617, 19122674.
38. Polakiewicz RD, Schieferl SM, Gingras AC, Sonenberg N, Comb MJ. mu-Opioid receptor activates signaling pathways implicated in cell survival and translational control. J Biol Chem 1998, 273:23534-41. 10.1074/jbc.273.36.23534, 9722592.
39. Tan M, Groszer M, Tan AM, Pandya A, Liu X, Xie CW. Phosphoinositide 3-kinase cascade facilitates mu-opioid desensitization in sensory neurons by altering G-protein-effector interactions. J Neurosci 2003, 23:10292-301.
40. Sanchez-Blazquez P, Rodriguez-Munoz M, Garzon J. Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling. PLoS One 2010, 5:e11278. 10.1371/journal.pone.0011278, 2890584, 20585660.